European Companies Search Engine

Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

Valneva SE, Lyon, France

Watch
Valneva SE

If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company.

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Create Dossier
Valneva SE

The dossier is a printable PDF file, summarizing information and publications for this company. The creation of dossiers is included in your subscription. After the creation of the dossier is completed, it will be sent to your email address .

Add to dossier (if available):

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Name

Valneva SE
Vivalis SA

Identification

Sirul
Siren 422497560
Stockp
VLA.PA INRLF VALN VLAP.PA
Siret
Siret 42249756000116
Lei
969500DIVIP5VKNW4948
EUID
FR4401.422497560

Address

12 Quai Perrache, 69002 Lyon, France
Saint-Herblain, France
Lyon cedex, France
Sèvremoine, France

Corporate purpose

2836
Biological Products, (No Diagnostic Substances)

The Company's objectives, in France and in all countries, are: research and development in the field of biomedicine and pharmacology; the commercial exploitation of patents and know-how; trade in products of all kinds and the provision of services in the field of data processing and information technology; the production, control and marketing of all products, services and research programmes with applications in human and animal health using molecular and cellular biology technologies and all related techniques; the participation of the Company, by any means, directly or indirectly, in any … Show more

Financial performance

Employees

For this company, Employees numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

History

Persons

Marketing & Tech

Network

Loading network

Legal Structure

Current legal representatives Legal form information Premium
Premium
1Chair of the board
1Director-General
1President
4Director
1Deputy Chair of the Supervisory Board
1Chair of the Supervisory Board
9Member of the Supervisory Board
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more

Learn more View plans
tax haven banner
Ownership relations Premium + Ownership & Flags add-on
Premium + Ownership & Flags add-on
Portfolio and Investments
3 known active shareholdings
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more

Learn more View plans

Financials

Key Performance Indicators Financial · Mktg & Tech Premium
Premium
Base/share capital
Total assets
Earnings
Revenue
Revenue CAGR
Return on sales
Equity
Equity ratio
Return on equity
Employee number
Revenue per employee
Taxes
Cash on hand
Receivables
Liabilities
Patents
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more

Learn more View plans
Annual report  
Financial Statements Interactive sheets with CSV/Excel download Premium
Premium
Balance
from 2005 to 2025
Profit & Loss
from 2005 to 2025
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more

Learn more View plans

Publications

24 Jun 2026
Patent: Method for the preparation of pharmaceutical compositions with immunogenic chikungunya virus Chikv-Delta5NSP3
21 Jun 2026
Capital: €28.5M
20 Jun 2026
European Union Transparency Register
4 Jun 2026
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
2 Apr 2026
Capital: €26.1M
17 Mar 2026
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
28 Feb 2026
Director: Gerd W. Zettlmeissl · No longer Deputy Director-General (4) · No longer Director: Sa à Conseil d'Administration Bpifrance Participations
26 Feb 2026
Capital: €26M
23 Jan 2026 also 17/06/2016
New headquarters
31 Dec 2025
Balance sheet for 31/12/2025 · Earnings statement for 31/12/2025
16 Dec 2025
Address · Segment clas­si­fi­ca­tion
3 Dec 2025
Capital: €25.8M
20 Nov 2025
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
5 Oct 2025
Capital: €25.8M
3 Sept 2025
Patent: Method for restoring and generating a virus in bird cells
12 Aug 2025
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
15 Jul 2025
Capital: €25.5M
4 Jul 2025
Capital: €25.1M
7 May 2025
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
24 Mar 2025
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
22 Jan 2025
Capital: €24.4M
31 Dec 2024
Balance sheet for 31/12/2024 · Earnings statement for 31/12/2024
28 Nov 2024
Capital: €24.4M
7 Nov 2024
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
1 Nov 2024 in Fts
EU funding (€2,128,503): 101168024 - Resilience-R-2023 - First Research Action for Medical Counter Measures Performed in the Frame of the Resilience FPA Consortium
1 Nov 2024 in Fts
EU funding (€1,096,141): 101168024 - Resilience-R-2023 - First Research Action for Medical Counter Measures Performed in the Frame of the Resilience FPA Consortium
30 Oct 2024
Capital: €24.3M
13 Sept 2024
Director: D. Guyot - Caparros · Capital: €20.9M
13 Sept 2024
No longer Deputy Director-General (1) · Capital: €20.9M
13 Aug 2024
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
6 Jun 2024
Capital: €20.9M
7 May 2024
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
22 Mar 2024
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
13 Mar 2024
Patent: Virus cleaning
28 Feb 2024
Patent: Zika virus purification
1 Feb 2024
Chair: Anne-Marie Salaun · No longer Pres.: Thomas Lingelbach · No longer Chair SB: Frédéric Grimaud · No longer VP: James Sulat · Director (4) · Dep.DG (6) · No longer Director (5) · No longer SB (4 …
31 Dec 2023
Balance sheet for 31/12/2023 · Earnings statement for 31/12/2023
9 Nov 2023
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
30 Sept 2023
Member of the Supervisory Board: Ute Jansen · Capital: €20.8M
28 Sept 2023
Capital: €20.8M
21 Sept 2023
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
6 Sept 2023
Annual report for the year ending 31/12/2022 · Balance sheet for 31/12/2022 · Earnings statement for 31/12/2022
11 Aug 2023
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
6 Jul 2023
Capital: €20.8M
4 May 2023
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
18 Apr 2023
Capital: €20.8M
18 Apr 2023
Capital: €20.8M
30 Mar 2023
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
13 Jan 2023
Capital: €20.8M
5 Jan 2023
Director (1) · Capital: €20.8M
2 Jan 2023
Director (1)
31 Dec 2022
Balance sheet for 31/12/2022 · Earnings statement for 31/12/2022
27 Dec 2022
Director (1)
7 Dec 2022
Capital: €20.8M
1 Dec 2022
Capital: €20.8M
10 Nov 2022
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
4 Nov 2022
President: James Sulat
26 Oct 2022
Wordmark: “VALNEVA TRAVEL HEALTH“
14 Oct 2022
President: Frédéric Grimaud
20 Sept 2022
Vice president: James Sulat
16 Sept 2022
Member of the Supervisory Board: James E. Connolly, Maïlys F. E. Ripert · Member of the Supervisory Board: Bpifrance Participations · Capital: €17.6M
16 Sept 2022
Capital: €17.6M
7 Sept 2022
Member of the Supervisory Board: James E. Connolly · Member of the Supervisory Board: Bpifrance Participations SA
5 Sept 2022
Vice president: James Sulat
12 Aug 2022
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
12 Aug 2022
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
9 Aug 2022
Vice president: James Sulat
20 May 2022
Capital: €16.2M
14 Apr 2022
Capital: €16.1M
8 Apr 2022
Patent: Human Metapneumovirus Combination Vaccine
8 Apr 2022
Patent: Human Metapneumo Virus Vaccine
31 Mar 2022
Capital: €15.9M
31 Mar 2022
Capital: €16.1M
25 Mar 2022
Reg­is­tra­tion: 25/03/2022 · Address · Legal form: Société européenne · Name: VALNEVA · Segment clas­si­fi­ca­tion
24 Mar 2022
U.S. Securities and Exchange Commission's Electronic Data Gathering, Analysis, and Retrieval system
18 Mar 2022
Director (1) · Capital: €15.8M
18 Mar 2022
Capital: €15.8M
15 Mar 2022
Wordmark: “VIVA|Screen“
9 Mar 2022
Director (1)
9 Mar 2022
Capital: €15.8M
7 Mar 2022
Deputy Chair of the Supervisory Board: James Sulat
22 Feb 2022
Capital: €15.8M
19 Jan 2022
President: James Sulat · Vice president: James Sulat
31 Dec 2021
President: James Sulat · Vice president: James Sulat
31 Dec 2021
Balance sheet for 31/12/2021 · Earnings statement for 31/12/2021
9 Dec 2021
Word figurative mark: “From cells to therapeutics Vivalis“
12 Nov 2021
Capital: €15M
22 Oct 2021
Wordmark: “VIVALIS“
30 Sept 2021
Capital: €15M
21 Sept 2021
Capital: €15M
9 Jul 2021
Capital: €15M
3 Jun 2021
No longer Member of the Supervisory Board: Thomas Casdagli · Capital: €13.8M
31 May 2021
Wordmark: “Vaxeos“
25 May 2021
No longer Member of the Supervisory Board: Thomas Th. Casdagli
9 Apr 2021
Capital: €13.8M
31 Jan 2021
Capital: €13.6M
31 Jan 2021
Capital: €13.6M
6 Jan 2021
No longer Director: Wolfgang Bender · Capital: €13.6M
31 Dec 2020
Balance sheet for 31/12/2020 · Earnings statement for 31/12/2020
28 Dec 2020
No longer Director: Wolfgang Leo Bender
3 Dec 2020
No longer Director: David Lawrence · Director (1) · Capital: €13.6M
27 Nov 2020
Word figurative mark: “VIVALIS“
24 Nov 2020
No longer Director: David Muir Lawrence · Director (1)
25 Oct 2020
Capital: €13.6M
14 Oct 2020
Capital: €13.6M
8 Sept 2020
Member of the Supervisory Board: Johanna W. Pattenier, Sharon E. Tetlow · VP: James Sulat · No longer SB: Sandra Edna Poole, Alexander Von Gabain · No longer VP: Louisa Mary Shaw · Capital: €13.6M
20 Aug 2020
Capital: €13.6M
10 Aug 2020
Patent: Chikungunya vaccine formulations
10 Aug 2020
Patent: Single vaccination against chikungunya virus
28 Jun 2020
Capital: €13.8M
19 May 2020
Patent: A Subunit Vaccine for Treatment or Prevention of a Respiratory Tract Infection
6 Mar 2020
Member of the Supervisory Board: Thomas Casdagli · No longer Member of the Supervisory Board: Balaji Muralidhar · Capital: €13.8M
26 Feb 2020
Member of the Supervisory Board: Thomas Th. Casdagli · No longer Member of the Supervisory Board: Balaji Muralidhar
12 Jan 2020
Capital: €13.8M
31 Dec 2019
Balance sheet for 31/12/2019 · Earnings statement for 31/12/2019
22 Nov 2019
Patent: Food with avian stem cells
5 Sept 2019
Capital: €13.8M
9 Aug 2019
Vice president: Louisa Shaw-Marotto · No longer Vice president: James Sulat · No longer Member of the Supervisory Board (3) · No longer SB: Bpifrance Participations · Capital: €13.8M
31 Jul 2019
Vice president: Louisa Mary Shaw · No longer Vice president: James Sulat · No longer SB (3) · Auditor: Deloitte & Associes SA · No longer SB: Bpifrance Participations SA · No longer Auditor: Beas SAS
26 Jun 2019
Patent: Avian Cell Lines for Producing Useful Substances
23 Jun 2019
Capital: €13.8M
5 Jun 2019
Patent: Aseptic cleaning procedure for viruses
29 May 2019
No longer Director: Thomas Lingelbach
27 May 2019
President: Thomas Lingelbach · Member of the Supervisory Board: Balaji Muralidhar
31 Dec 2018
Balance sheet for 31/12/2018 · Earnings statement for 31/12/2018
7 Nov 2018
Patent
26 Oct 2018
Capital: €13.8M
17 Oct 2018
Member of the Supervisory Board: Louisa Mary Shaw
27 Jul 2018
President: Thomas Lingelbach · Chair of the Supervisory Board: Frédéric Grimaud · Vice president: James Sulat · Director (5) · SB (10) · DG (1) · SB: Bpifrance Participations · Auditor (3 companies)
25 Jul 2018
Member of the Supervisory Board: Balaji Muralidhar
18 Jul 2018
President: Thomas Lingelbach · Chair SB: Frédéric Grimaud · VP: James Sulat · Director (5) · SB (9) · DG (1) · SB: Bpifrance Participations, Bpifrance Participations SA · Auditor (3 companies)
1 Jul 2018
Address
31 Dec 2017
Balance sheet for 31/12/2017 · Earnings statement for 31/12/2017
26 Sept 2017
Director: Wolfgang Bender, David Lawrence
26 Sept 2017
Capital: €11.8M
20 Sept 2017
Word figurative mark: “VIP, valneva in partnership“
6 Sept 2017
Director: Wolfgang Leo Bender, David Muir Lawrence
25 Aug 2017
Member of the Supervisory Board: Muralidhar Balaji, Poole Sandra · No longer Auditor (1)
7 Aug 2017
Member of the Supervisory Board: Balaji Muralidhar, Sandra Edna Poole · No longer Auditor (1)
23 Jun 2017
Capital: €11.8M
23 May 2017
No longer Director: Reinhard Kandera · Director (1)
8 Mar 2017
Patent: Method for Screening Cells
3 Feb 2017
Capital: €11.8M
31 Dec 2016
Balance sheet for 31/12/2016 · Earnings statement for 31/12/2016
Year 2016 in Epobase
6 European patent filings: Virus Purification …
5 Aug 2016
Member of the Supervisory Board: Ralf Leo Clemens, Maïlys F. E. Ripert, Louisa Shaw-Marotto · No longer Member of the Supervisory Board: Michel Greco, Hans Wigzell · SB: Bpifrance Participations
12 Jul 2016
President: Frédéric N.N. Lingelbach · VP: James Sulat · SB (7) · DG (1) · Director (3) · Auditor (1) · SB: Bpifrance Participations SA à conseil d'administration · Auditor (3 companies)
13 May 2016
Address
3 Feb 2016
Wordmark: “EB66“
31 Dec 2015
Balance sheet for 31/12/2015 · Earnings statement for 31/12/2015
29 Nov 2015
Patent: Mikrowell-Array-Chip zum Nachweis eines Antigenspezifischen Lymphozyten, Verfahren zum Nachweis eines Antigenspezifischen Lymphozyten und Verfahren zur Klonierung eines Antigenrezeptorgens …
Year 2015 in Epobase
4 European patent filings: Method to Clone a Single Antigen-Specfic Lymphocyte. …
16 Oct 2015
Capital: €11.4M
27 Sept 2015
Capital: €11.4M
10 Sept 2015
Capital: €11.4M
8 Jul 2015
Capital: €11.4M
7 Jun 2015
Word figurative mark: “EB...“
25 Mar 2015
Capital: €11.4M
31 Dec 2014
Balance sheet for 31/12/2014 · Earnings statement for 31/12/2014
10 Dec 2014
Capital: €8,631,142
24 Aug 2014
Capital: €8,630,317
13 Aug 2014
Capital: €8,555,317
25 Jul 2014
Capital: €8,465,317
24 Apr 2014
Capital: €8,390,317
26 Mar 2014
Capital: €8,389,717
11 Mar 2014
Word figurative mark: “VALNEVA“
27 Jan 2014
Word figurative mark: “V“
9 Jan 2014
SB: Anne-Marie Salaun · Auditor (1) · No longer Auditor (1) · Auditor: Pricewaterhousecoopers Audit · No longer Auditor: Sa Cabinet Gerard Chesneau et Associes · Capital: €8,367,584
31 Dec 2013
Balance sheet for 31/12/2013 · Earnings statement for 31/12/2013
26 Dec 2013
Capital: €8,370,659
13 Nov 2013
Patent: Duck Embryonic Derived Stem Cell Lines for the Production of Viral Vaccines
10 Nov 2013
Capital: €8,369,159
9 Oct 2013
No longer Director (1)
25 Sept 2013
Director: Anne-Marie Salaun · Auditor (1) · No longer Auditor (1) · Auditor: Pricewaterhousecoopers Audit · No longer Auditor: Sa Cabinet Gerard Chesneau et Associes · Capital: €8,367,584
1 Sept 2013 in Fts
EU funding (€1,799,304): Tumador
10 Jul 2013
Capital: €6,092,802
7 Jun 2013
Pres.: Thomas Lingelbach · VP: James Sulat · Director (4) · SB (4) · DG (1) · No longer Pres. (1) · No longer DG (2) · No longer Director (1) · No longer SB (2) · No longer VP (1) …
28 May 2013
Address · Legal form: Société européenne · Name: VALNEVA
6 Feb 2013 as Vivalis SA à directoire et conseil de surveillance
Capital: €3,224,379
5 Feb 2013 as Vivalis SA à directoire et conseil de surveillance
Capital: €3,224,379
31 Dec 2012
Balance sheet for 31/12/2012 · Earnings statement for 31/12/2012
25 Dec 2012 as Vivalis SA à directoire et conseil de surveillance
Capital: €3,201,414
11 Dec 2012 as Vivalis SA à directoire et conseil de surveillance
Capital: €3,193,638
16 Oct 2012 as Vivalis SA à directoire et conseil de surveillance
Capital: €3,188,688
10 Apr 2012 as Vivalis SA à directoire et conseil de surveillance
Capital: €3,172,617
25 Jan 2012
Wordmark: “SMOL“
13 Jan 2012
Patent
31 Dec 2011
Balance sheet for 31/12/2011 · Earnings statement for 31/12/2011
Year 2011 in Euipotm
4 trademark filings (3 wordmarks, 1 word figurative mark): EB66, VIVALIS, VIVA|Screen …
7 Dec 2011
Patent: Microwell Array Chip for Detecting Antigen-Specific Lymphocyte, Method of Detecting Antigen-Specific Lymphocyte and Method of Cloning Antigen-Specific Lymphocyte Antigen Receptor Gene
9 Nov 2011
Patent: Method of Screening by Using Conformation Sensitive Peptides
23 Oct 2011 as Vivalis SA à directoire et à conseil de surveillance
Capital: €3,167,616
13 Sept 2011 as Vivalis SA à directoire et à conseil de surveillance
Capital: €3,152,016
3 Aug 2011 as Vivalis SA à directoire et à conseil de surveillance
Chair of the Supervisory Board: Frédéric Grimaud · Member of the Supervisory Board (4) · DG (2) · Pres. (1) · VP (1) · Auditor (1) · SB: Groupe Grimaud la Corbiere (SAD) · Auditor (3 companies)
8 Mar 2011 as Vivalis SA à directoire et à conseil de surveillance
Capital: €3,149,047
4 Feb 2011
Patent: FED-Batch Process Using Concentrated Cell Culture Medium for the Efficient Production of Biologics in EB66 Cells
31 Dec 2010
Balance sheet for 31/12/2010 · Earnings statement for 31/12/2010
22 Sept 2010 as Vivalis SA à directoire et à conseil de surveillance
Capital: €3,145,029
11 Aug 2010 as Vivalis SA à directoire et à conseil de surveillance
Capital: €2,246,450
15 Jul 2010 as Vivalis SA à directoire et à conseil de surveillance
Capital: €2,223,245
11 Mar 2010 as Vivalis SA à directoire et à conseil de surveillance
Capital: €2,219,870
31 Dec 2009
Balance sheet for 31/12/2009 · Earnings statement for 31/12/2009
22 Oct 2009 as Vivalis SA à directoire et à conseil de surveillance
Capital: €2,219,420
4 Mar 2009 as Vivalis SA à directoire et à conseil de surveillance
Capital: €2,191,955
31 Dec 2008
Balance sheet for 31/12/2008 · Earnings statement for 31/12/2008
19 Nov 2008
Patent: Aviäre Zelllinien für die Herstellung von nützlichen Substanzen
23 Apr 2008
Patent: Duck Embryonic Derived Stem Cell Lines for the Production of Viral Vaccines
4 Mar 2008 as Vivalis SA à directoire et à conseil de surveillance
Capital: €2,175,095
9 Jan 2008
Patent: Verfahren zur Herstellung von Virusimpfstoffen in AUS Vogelembryonen Stammenden Stammzellinien in Suspension
1 Jan 2008 as Vivalis SA
Segment clas­si­fi­ca­tion
31 Dec 2007
Balance sheet for 31/12/2007 · Earnings statement for 31/12/2007
9 Aug 2007
Patent: Method of Production of Transgenic Avian Using Embryonic Stem Cells
9 Aug 2007
Patent: Method of Production of Transgenic Avian Using Embryonic Stem Cells
31 Dec 2006
Balance sheet for 31/12/2006 · Earnings statement for 31/12/2006
19 Oct 2006
Patent: Verfahren zur Herstellung von Virusimpfstoffen in AUS Vogelembryonen Stammenden Stammzellinien in Suspension
31 Dec 2005
Balance sheet for 31/12/2005 · Earnings statement for 31/12/2005
25 Dec 2003 as Vivalis SA
Legal form: SA à directoire (s.a.i.)
24 Mar 1999 as Vivalis SA
Address · Legal form: SA à conseil d'administration (s.a.i.) · Name: VIVALIS
There are no publications matching your search.

Mentions

18 Jun 2026 in Rne
Reg­is­tra­tion: 23/09/2019 · DG: Thomas Lingelbach · Chair: Anne-Marie Salaun · VP: James Sulat · Director (4) · Auditor: Deloitte & Associes SA, Pricewaterhousecoopers Audit SAS · Capital: €28.5M
30 Jul 2025 in Ler
Direct parent: Valneva Austria GmbH
30 Jul 2025 in Ler
Ultimate parent: Valneva Austria GmbH
13 May 2025 in Psc
Companies House - Persons with Significant Control
4 Sept 2024 in Psc
Companies House - Persons with Significant Control
via Firmenbuch in Bmjfbv
Shareholdings: Valneva Austria GmbH, Valneva Austria GmbH, Valneva Austria GmbH · Shareholding: Valneva Austria GmbH
9 Aug 2023 in Ler
Ultimate parent: Valneva Sweden AB
30 Dec 2014 in Wzfma
Change of shareholdings: Valneva Austria GmbH
17 Sept 2013 in Wzfma
Shareholding: Valneva Austria GmbH
31 Jul 2013 in Wzfma
Shareholding: INTERCELL Austria AG
There are no publications matching your search.

The data on this page is generated by a fully automated algorithm. It may have errors, and is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.

Printing is only available to North Data premium service subscribers.